Product Code:461000
Published Date: Jan 09,2023
Pages: 72
Region: Global
Category: Chemical & Material
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
PDF DOWNLOAD
GET FREE SAMPLE
CUSTOMIZE REQUEST
Provide comprehensive and accurate analysis and reports according to your exact requirements
Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator). Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus. LPI (LP Information)' newest research report, the “Medical Inhaled Nitric Oxide Industry Forecast” looks at past sales and reviews total world Medical Inhaled Nitric Oxide sales in 2022, providing a comprehensive analysis by region and market sector of projected Medical Inhaled Nitric Oxide sales for 2023 through 2029. With Medical Inhaled Nitric Oxide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medical Inhaled Nitric Oxide industry. This Insight Report provides a comprehensive analysis of the global Medical Inhaled Nitric Oxide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Medical Inhaled Nitric Oxide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Medical Inhaled Nitric Oxide market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medical Inhaled Nitric Oxide and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medical Inhaled Nitric Oxide. The global Medical Inhaled Nitric Oxide market size is projected to grow from US$ 1024.3 million in 2022 to US$ 1278.4 million in 2029; it is expected to grow at a CAGR of 1278.4 from 2023 to 2029. The main medical inhaled Nitric Oxide players include Mallinckrodt, Linde, Air Liquide, etc. The top three Medical Inhaled Nitric Oxide players account for approximately 95% of the total global market. The global medical inhaled Nitric Oxide are mainly produced in United States and Europe, they occupied for a share about 95%. North America is the largest consumer market, accounting for about 77%, followed by Europe and Asia-Pacific, with around 16% and 6% market share respectively. This report presents a comprehensive overview, market shares, and growth opportunities of Medical Inhaled Nitric Oxide market by product type, application, key manufacturers and key regions and countries. Market Segmentation: Segmentation by type 800 ppm 100 ppm Other Segmentation by application Near-term and Pre-term Infants PPHN Children and Adult ARDS Other Diseases This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Mallinckrodt Linde Air Liquide Key Questions Addressed in this Report What is the 10-year outlook for the global Medical Inhaled Nitric Oxide market? What factors are driving Medical Inhaled Nitric Oxide market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Medical Inhaled Nitric Oxide market opportunities vary by end market size? How does Medical Inhaled Nitric Oxide break out type, application? What are the influences of COVID-19 and Russia-Ukraine war?